Trials / Completed
CompletedNCT00856193
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Matching placebo capsules were supplied for inhalation once daily with Concept 1 device. |
| DRUG | NVA237 | NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device. |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2009-03-05
- Last updated
- 2016-09-14
- Results posted
- 2011-05-06
Locations
2 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00856193. Inclusion in this directory is not an endorsement.